Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146289 · ClinicalTrials.gov registry record · Phase 2
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00146289 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 138 participants.
The verdict
NCT00146289, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
Interventions
- DRUG MICARDIS® (telmisartan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146289
The ClinicalTrials.gov registry entry for NCT00146289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MICARDIS® (telmisartan) is the first listed.
NCT00146289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146289 about?
NCT00146289 is a clinical study titled "The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects". The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
What is the current status of trial NCT00146289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2005-02.
What interventions are being tested in trial NCT00146289?
The interventions under investigation include: MICARDIS® (telmisartan) (DRUG).
Who is sponsoring clinical trial NCT00146289?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.